Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study

KARAAĞAÇ M., ARTAÇ M., SEZGİN GÖKSU S., Eryilmaz M. K., COŞKUN H. Ş., Bozcuk H.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.4, sa.2, ss.172-176, 2020 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 4 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.14744/ejmo.2020.15578
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.172-176
  • Anahtar Kelimeler: Chemotherapy, ifosfamide, irinotecan, small cell lung cancer, survival, PHASE-II TRIAL, COMPARING CISPLATIN, ETOPOSIDE, CHEMOTHERAPY, CARBOPLATIN, TOPOTECAN, 2ND-LINE, EFFICACY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Objectives: Recurrent and progressive small cell lung cancer (SCLC) has a very poor prognosis, and treatment options are limited. Combination of irinotecan with ifosfamide ( I-I regimen) in SCLC has limited preliminary data. In this study, we aimed to evaluate the efficacy and toxicity of I-I regimen in patients with previously treated SCLC.